June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Ocular Hypotensive Activity Of A New Melatonin Analog OPD-11, In Normotensive Rabbits
Author Affiliations & Notes
  • Maria Caballo Gonzalez
    Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
  • Carmen del Campo
    Pharmaceutical and Organic Chemistry, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
  • Loreto Salazar
    Pharmaceutical and Organic Chemistry, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
  • Vanessa Andres-Guerrero
    Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
  • Marta Vicario de la Torre
    Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
  • Rocio Herrero-Vanrell
    Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
  • Irene Molina-Martínez
    Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy/Complutense Univ., Madrid, Spain
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1992. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria Caballo Gonzalez, Carmen del Campo, Loreto Salazar, Vanessa Andres-Guerrero, Marta Vicario de la Torre, Rocio Herrero-Vanrell, Irene Molina-Martínez; Ocular Hypotensive Activity Of A New Melatonin Analog OPD-11, In Normotensive Rabbits. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1992.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The main risk factor in the development of glaucoma is an elevated intraocular pressure (IOP). It has been shown that the topical application of melatonin analogs, such as 5-MCA-NAT, can effectively reduce IOP. OPD-11 is a new melatonin analog able to decrease IOP in normotensive rabbits. The role of dissacharides, as protectant compounds against cells dissecation, has been previously investigated. The aim of this work was to prepare new ophthalmic formulations of OPD-11 (100 µM) containing fructose (F) or trehalose (T) to be administered by topical route. In vitro tolerance and in vivo efficacy of these formulations were also determined.

Methods: Two formulations were prepared. OPD-11 was first dissolved in propylene glycol and then diluted with an isotonic solution with F or T. Final formulations were composed of OPD-11 (100 µM) and F 2% or T 2% (OPD-11/F and OPD-11/T, respectively). Osmolarity, viscosity, surface tension and pH were assessed. In vitro cytotoxicity was evaluated in normal human conjunctival cells at different exposure times (15 min, 1 h and 4 h). The ocular hypotensive effect was evaluated after instillation (25 µL) in normotensive rabbits (n=20 eyes) for 8 h. As control, animals received vehicle without OPD-11. All the in vivo experiments were conducted in compliance with the ARVO statements for the Use of Animals in Ophthalmolgy and Vision Research.

Results: OPD-11/F and OPD-11/T showed pH values nearly neutral, were within the range of isotonicity and satisfied the requirements of surface tension and viscosity for ophthalmic solutions. Cytotoxicity assays showed good tolerance in conjunctival cells for both formulations (cell viability>80% at all exposure times). OPD-11/F and OPD-11/T were able to maintain a hypotensive activity providing similar effects. Non significant differences were found between the maximum IOP reduction reached by both formulations (p>0.05; OPD-11/F: 21.32 ± 4.7%, OPD-11/T: 20.70 ± 3.7%). The hypotensive activity lasted 5h and 6h for OPD-11/F and OPD-11/T, respectively. The time of maximum effect was 3 hours in both cases.

Conclusions: Formulations containing the new agent OPD-11 (100 µM) and fructose or trehalose (2%) showed suitable properties for topical ophthalmic application. Besides, both formulations were capable of providing a hypotensive effect in normotensive rabbits. OPD-11 should be considered potentially useful in the treatment of glaucoma.

Keywords: 590 melatonin • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×